BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

Preclinical publications highlighted in BioCentury’s Distillery this year identified white space target opportunities including untapped E3 ubiquitin ligases, vesicular regulators and ion channels, as...
BioCentury | Oct 31, 2020
Translation in Brief

A method to collect tumor-specific T cells; plus research from Heidelberg University, Black Diamond, KSQ and SynDevRx

Isolating tumor antigen-specific T cellsScripps Research Institute scientists have described in Cell a method, coined FucoID, to detect and separate T cells that react to tumor-specific antigens from bystander T cells. In FucoID, which is based on...
BioCentury | Oct 28, 2020
Product Development

Angelman trial pause for antisense oligo comes with efficacy data that lift Ultragenyx shares

GeneTx and Ultragenyx will look to adjust dosing and administration in their Phase I/II trial of GTX-102 to treat Angelman syndrome after patients experienced a serious adverse event thought...
BioCentury | Oct 27, 2020
Distillery Therapeutics

PCF11 binding site on E3 ubiquitin ligase MAGEA11 identified as neuroblastoma target

DISEASE CATEGORY: Cancer INDICATION: Neuroendocrine tumors Interrupting the interaction between the oncogenic E3 ubiquitin ligase MAGEA11 and its substrate PCF11 could treat neuroendocrine tumors. Crystallographic analysis of the MAGEA11-PCF11 complex identified a shallow cleft on...
BioCentury | Oct 24, 2020
Translation in Brief

UNC Chapel Hill Angelman gene therapy rescues motor function; plus data backing planned Pacylex, Kronos clinical trials and more

AAV gene editing therapy for Angelman syndromeUniversity of North Carolina at Chapel Hill scientists have created a CRISPR gene therapy for Angelman syndrome that ameliorated motor function deficits in a mouse model of the maternally...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

As targeted protein degradation grows up, the field is going after harder targets and new mechanisms of action. Over the last year, a series of Phase I/II readouts from front-runner Arvinas Inc. (NASDAQ:ARVN),...
BioCentury | Sep 10, 2020

Casma to advance muscle dystrophy candidate into the clinic with $50M series B

A $50 million series B round led by The Column Group will provide Casma with enough cash to bring its lead Duchenne muscular dystrophy program into the clinic in early 2022.  Launched in 2018, Casma...
BioCentury | Aug 22, 2020
Emerging Company Profile

Amphista: broadening the target space of protein degradation

Amphista aims to apply protein degradation to a broader set of targets and indications using an approach that does not depend on E3 ubiquitin ligases. The Glasglow-based company spun out of the University of Dundee,...
BioCentury | Jun 26, 2020

June 25 Quick Takes: Chi-Med rakes in $100M; plus bank rules rolled back, newco DeCART has June ties and more

Chi-Med raises $100M private placement Hutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) raised $100 million Thursday in a private placement to General Atlantic through the sale of 4 million ADSs at $25. The price matches its...
BioCentury | May 27, 2020
Emerging Company Profile

Versant’s Monte Rosa debuts with $32.5M, library of molecular glues for protein degradation

Monte Rosa has built a library of small molecule protein degraders that make broader use of the “degron” structures grabbed by the field’s first drugs, thalidomide derivatives. Launched from Versant Ventures’ Swiss incubator lab Ridgeline,...
Items per page:
1 - 10 of 425